Business Wire

Accuity Releases Bankers Almanac Enhanced Due Diligence to Automate Risk Assessments for Financial Counterparty KYC

13.1.2021 12:00:00 EET | Business Wire | Press release

Share

Accuity, the leading global provider of financial crime screening, payment services, and know your customer (KYC) solutions, has announced the availability of Bankers Almanac Enhanced Due Diligence, a new solution that will enable banks to conduct efficient and effective KYC risk assessments of their financial counterparties within a single application. Accuity has brought together two of its solutions, Bankers Almanac: Counterparty KYC and Firco Compliance Link, to create an ‘out-of-the-box' SaaS platform that automates the enhanced due diligence (EDD) reports and audit trails required to meet regulatory guidance.

Bankers Almanac Enhanced Due Diligence helps banks meet ever-increasing regulatory expectations, while improving operational efficiency and minimising the mounting cost of compliance. It addresses these issues by:

  • Providing detailed documentation of the risk identification process for greater transparency, including an electronic audit trail of all actions taken
  • Automating the financial counterparty KYC and financial crime screening processes within a single interface
  • Bringing down the total cost of ownership (TCO) of the KYC process by streamlining systems and reducing manual tasks.

Regulatory pressure on the financial services industry continues to build. The FinCEN Files - a leak of thousands of Suspicious Activity Reports in 2020 - was a stark reminder of the role financial institutions hold as gatekeepers of the financial system and suggested banks must go further to report financial crime risks more effectively. However, the burden of compliance on a bank’s resources remains a sticking point; 76% of financial institutions find onerous processes a challenge when conducting KYC, according to findings from the Accuity KYC survey.

When forming new correspondent banking relationships or reviewing existing partnerships, banks are required to perform due diligence, including sanctions, politically exposed persons (PEP) and adverse media screening, to create a risk profile for each financial counterparty. This is often a highly laborious task, requiring KYC analysts to access multiple systems, source information manually from correspondent banks, and conduct screening, before compiling the final assessment report. This process is repeated at regular intervals to ensure the risk assessment remains up to date.

Bankers Almanac Enhanced Due Diligence automates the risk identification process. The solution connects the comprehensive Bankers Almanac data set of more than 200,000 global financial institutions, including names, addresses, and ownership information, with Firco Compliance Link, which assesses sanctions and money laundering risk by screening entities against the full breadth of financial crime data. The solution uses API technology to integrate functionality from both solutions within one platform and generates a detailed automated risk report based on the screening results.

Dalbir Sahota, VP Bankers Almanac KYC, commented “Many of our clients across the globe want to make their financial counterparty KYC risk assessments more efficient and effective, and aspire to keep pace with the standards of the world’s largest banks. We have created Bankers Almanac Enhanced Due Diligence to give all banks access to a KYC solution that provides both automation and auditability in risk-based decision making, without the substantial investment of building and maintaining a complex in-house solution. The platform is ready to go straight ‘out-of-the-box’ and will help our clients keep up with international best practices, while maintaining trusted relationships with their correspondent banking partners.”

Bankers Almanac Enhanced Due Diligence is available from Accuity now. Demonstrations of the solution are available on request.

ENDS

Notes to editors:

About Accuity
Accuity powers compliant and assured client transactions to help build an interconnected and trusted financial ecosystem. Our financial crime screening, payment services, and benefits compliance solutions help enable financial inclusion while identifying criminal activity and fraudulent players. With deep expertise and industry-leading data and analytics solutions from the Firco and Bankers Almanac brands, Accuity provides unmatched confidence, efficiency and compliance for customers around the world. Part of RELX, a global provider of information and analytics for professional and business customers, Accuity has been delivering solutions to banks and businesses worldwide for 180 years.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Imogen Nash, Accuity (London)
imogen.nash@accuity.com / Tel: +44 (0) 7789 924 920

Jon Schubin, Cognito (London)
accuity@cognitomedia.com / Tel: +44 (0)20 7426 9400

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release

Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye